Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL

Atherosclerosis

Volumn 128, Issue 1, 1997, Pages 11-18

  Hussein, Osamah ^a   Schlezinger, Sorina ^a   Rosenblat, Mira ^a   Keidar, Shlomo ^a   Aviram, Michael ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Fluvastatin; Hypercholesterolemia; LDL lipid peroxidation; Statins

Indexed keywords

FLUINDOSTATIN; FREE RADICAL; LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; DRUG EFFECT; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; LIPID PEROXIDATION; LIPOPROTEIN METABOLISM; ORAL DRUG ADMINISTRATION; OXIDATION; PRIORITY JOURNAL;

ADULT; AGED; AMIDINES; ANTICHOLESTEREMIC AGENTS; COPPER SULFATE; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS, MONOUNSATURATED; FREE RADICAL SCAVENGERS; HUMANS; HYPERCHOLESTEROLEMIA; INDOLES; LIPID PEROXIDATION; LIPIDS; LIPOPROTEINS, LDL; MIDDLE AGED;

EID: 0031050342     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(96)05972-2     Document Type: Article

References (46)

1. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. New Eng J Med 1989;320(14):915-924.
2. Aviram M. Beyond cholesterol: modifications of lipoproteins and increased atherogenicity. In: Neri GG, Serneri GF, Gensini R, Abbate D and Prisco D (eds). Atherosclerosis, Inflammation and Thrombosis. Florence: Scientific Press, 1993;15-36.
3. Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: implication for cholesterol deposition in atherosclerosis. Annu Rev Biochem 1983;52:223-261.
4. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990's. Nature 1993;362(6423):801-809.
5. Badimon JJ, Fuster V, Chesebro JH, Badimon L. Coronary atherosclerosis. A multifactorial disease. Circulation 1993;87(3 Suppl II):3-16.
6. Witzum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991;88(6):1785-1792.
7. Aviram M. Modified forms of LDL and atherosclerosis. Atherosclerosis 1993;98:1-9.
8. Aviram M. Macrophage-mediated oxidation of LDL and atherosclerosis. In: Bellomo G, Finardi G, Maggi E and Rice-Evans C (eds). Free Radicals Lipoprotein Oxidation and Atherosclerosis: Biological and Clinical Aspects, Volume IX. London: Richelieu Press, 1995;101-137.
9. Aviram M. Oxidative modification of low density lipoprotein and atherosclerosis. Isr J Med Sci 1995;31:241-249.
10. Heinecke J.W. Cellular mechanisms for the oxidative modification of lipoprotein: implications for atherogenesis. Coronary Artery Dis 1994;5(3):205-210.
11. Aviram M, Rosenblat M. Macrophage-mediated oxidation of extracellular low density lipoprotein requires an initial binding of the lipoprotein to its receptor. J Lipid Res 1994;35:385-398.
12. Fuhrman B, Lavy A, Aviram M. Consumption of red wine with meals reduces the susceptibility of human plasma and low density lipoprotein to lipid peroxidation. Am J Clin Nutr 1995;61:549-554.
13. Fuhrman B, Aviram M. White wine reduces LDL susceptibility to oxidation in vitro but not in vivo. Am J Clin Nutr 1996;63:403-404.
14. Sato K, Miki E, Shimasaki H. Free radical-mediated chain oxidation of low density lipoprotein and its synergistic inhibition by vitamin E and vitamin C. Arch Biochem Biophys 1990;279(2):402-405.
15. Retsky KL, Freeman MW, Frei B. Ascorbic acid oxidation product(s) protect human low density lipoprotein against atherogenic modification. Anti- rather than prooxidant activity of vitamin C in the presence of transition metal ions. J Biol Chem 1993;268(2):1304-1309.
16. Lavy A, Ben Amotz A, Aviram M. Preferential inhibition of LDL oxidation by the all-trans isomer of β-carotene in comparison to the 9-cis-β-carotene. Europ J Clin Chem Clin Biochem 1993;31:83-90.
17. Levy Y, Ben-Amotz A, Aviram M. Effect of dietary supplementation of β-carotene to humans on its binding to plasma LDL and on the lipoprotein susceptibility to undergo oxidative modification: comparison of the synthetic all trans isomer with the natural algae β-carotene. J Nutr Environ Med 1994;5:13-22.
18. Aviram M. Antioxidant-mediated inhibition of macrophage modification of low density lipoprotein. Life Chem Rep 1994;12:69-78.
19. Lavy A, Brook JG, Dankner G, Ben Amotz A, Aviram M. Enhanced in vitro oxidation of plasma lipoproteins derived from hypercholesterolemic patients. Metabolism 1991;40:794-799.
20. Goldstein JL, Brown MS. Regulation of low-density lipoportein receptors: implications for pathogenesis and therapy of hypercholesterolemia and atherosclerosis. Circulation 1987;76(3):504-507.
21. Aviram M, Keidar S, Brooks JG. Dual effect of lovastatin and simvastatin on LDL-macrophage interaction. Eur J Clin Chem Clin Biochem 1991;29:657-664.
22. Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. New Eng J Med 1988;319:24-33.
23. Shepherd J. Fibrates and statins in the treatment of hyperlipidemia: in appraisal of their efficacy and safety. Eur Heart J 1995;16:5-13.
24. Raveh D, Israeli A, Arnon R, Eisenberg S. Effect of lovastatin therapy on LDL receptor activity in circulating monocytes and on structure and composition of plasma lipoproteins. Atherosclerosis 1990;82:19-26.
25. Aviram M, Dankner G, Cogan U, Hochgraf E, Brook JG. Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: in vitro and in vivo studies. Metabolism 1992;41(3):229-235.
26. Giroux LM, Davignon J, Naruszewicz M. Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages. Biochim Biophys Acta 1993;1165(3):335-338.
27. Hoffman R, Brook JG, Aviram M. Hypolipidemic therapy reduces lipoprotein susceptibility to undergo lipid peroxidation: in vitro and ex vivo studies. Atherosclerosis 1992;93:105-113.
28. Milani M, Cimminiello C, Merlo B, Lorena M, Arpaia G, Bonfardeci G. Effects of fluvastatin and pravastatin on lipid profiles and thromboxane production in type IIa hypercholesterolemia. Am J Cardiol 1995;76(2):51A-53A.
29. Levy RI, Troendle AJ, Fattu MA. A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin. Circulation 1993;87(Suppl):11145-11153.
30. Insull WJ, Black D, Dujovne C, Hosking JD, Hunninghake D, Keilson L, Knopp R, McKenney J, Stein E, Troendle AJ. Efficacy and safety of once-daily vs twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia. Arch Intern Med 1994;154(21):2449-2455.
31. Zavoral JH, Haggerty BJ, Winick AG, Bergmann SD. Efficacy of fluvastatin, a totally synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. FLUENT Study Group. Fluvastatin Long-Term Extension Trial. Am J Cardiol 1995;76(2):37A-40A.
32. Jacotot B, Benghozi R, Pfister P, Holmes D. Comparison of fluvastatin vs pravastatin treatment of primary hypercholesterolemia. French Fluvastatin Study Group. Am J Cardiol 1995;76(2):54A-56A.
33. Tse FL, Jaffe JM, Troendle A. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. J Clin Pharmacol 1992;32:630-638.
34. Smith HT, Jokubaitis LA, Troendle AJ, Hwang DS and Robinson WT. Pharmacokinetics of fluvastatin and specific drug intractions. Am J Hyperten 1993;6(11 part 2):3755-3825.
35. Ose L, Scott R. Doubl-blind comparison of the efficacy and tolerability of simvastatin and fluvastatin in patients with primary hypercholesterolemia. Clin Drug Invest 1995;10(3):127-138.
36. Frei B, Stoker R, Ames BN. Antioxidant defenses and lipid peroxidation in human blood plasma. Proc Natl Acad Sci USA 1988;85(24):9748-9752.
37. Buege JA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol 1978;52:302-310.
38. Aviram M. Plasma lipoprotein separation by discontinuous density gradient ultracentrifugation in hyperlipoproteinemic patients. Biochem Med 1983;30:111-118.
39. Lowry OH, Rosebrough NJ, Farr AL, Randall RS. Protein measurement with the folin phenol reagent. J Biol Chem 1951;193:265-275.
40. Esterbauer H, Striegl G, Puhl H, Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun 1989;6(1):67-75.
41. Chin HP, Blankenhorn DH. Separation and quantitative analysis of serum lipoproteins by means of electrophoresis on cellulose acetate. Clin Chim Acta 1968;20(2):305-314.
42. Blois MS. Antioxidant determination by the use of a stable free radical. Nature 1958;181:1199-1200.
43. Dahle LK, Hill EG, Holman RT. The thiobarbituric acid reaction and the autooxidation of polyunsaturated fatty acid methyl esters. Arch Biochem Biophys 1962;98:253-261.
44. Bligh EG, Dyer WJ. A rapid method for total lipid extraction and purification. Am J Biochem 1959;37:911-917.
45. Yuan JN, Tsai MY, Hegland J, Hunninghake DB. Effects of fluvastatin (XU-62-320), an HMG-CoA reductase inhibitor on the distribution and composition of low density lipoprotein subspecies in humans. Atherosclerosis 1991;87(2-3):147-157.
46. Aviram M. Oxidized LDL interaction with macrophages in atherosclerosis and the antiatherogenicity of antioxidants. Eur J Clin Biochem 1996;34:599-608.